EWTX - NASDAQ

Edgewise Therapeutics, Inc.

EWTX·NASDAQ

$36.21

-1.7%

HealthcareBiotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.90B

EPS-1.6300

P/E Ratio-22.21

Earnings Date08/06/2026

ewtx

Other Current Assets

Last Annual Value

13.28M

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Edgewise Therapeutics, Inc. Competitors Analysis of Other Current Assets

EWTX · NASDAQ

Company	Other Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Edgewise Therapeutics, Inc. NASDAQ:EWTX	13.28M	15.6%	N/A	N/A
uniQure N.V. NASDAQ:QURE	20.51M	97.7%	50.3%	32.0%
Vera Therapeutics, Inc. NASDAQ:VERA	11.01M	50.7%	87.1%	N/A
Structure Therapeutics Inc. NASDAQ:GPCR	124.11M	170.3%	N/A	N/A
Viridian Therapeutics, Inc. NASDAQ:VRDN	19.58M	29.5%	N/A	60.7%
Nuvation Bio Inc. NYSE:NUVB	11.54M	96.6%	N/A	N/A
Celldex Therapeutics, Inc. NASDAQ:CLDX	14.08M	37.1%	N/A	N/A
Janux Therapeutics, Inc. NASDAQ:JANX	0.00	N/A	N/A	N/A
Ocular Therapeutix, Inc. NASDAQ:OCUL	10.86M	11.0%	N/A	22.8%

Edgewise Therapeutics, Inc. Fair Value Envelope

EWTX · NASDAQ

Our analysis suggests that EWTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $36.21, this represents a potential HIDDEN relative to our calculated worth for Edgewise Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $36.21

Related Guides

Blog Categories

Continue your EWTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.